1. Introduction
===============

Colorectal adenocarcinoma is one of the most common cancers in the world with over 1.8 million new colorectal adenocarcinomas estimated to have occurred in 2018.^\[[@R1]\]^ Colorectal adenocarcinoma is the second most frequently diagnosed cancer and the fourth leading cause of cancer death in Korea.^\[[@R2]\]^ Surgical excision is the first choice for curing colorectal adenocarcinoma, and adjuvant systemic therapy including immunotherapy can improve survival.^\[[@R3],[@R4]\]^ Although the mortality is decreasing, the prognosis of some colorectal adenocarcinoma is still poor. New prognostic factors that can stratify patients into different risk groups are needed.^\[[@R4]\]^

Mesothelin is a cell-surface glycoprotein that is normally present on the mesothelial cells lining human body cavities.^\[[@R5]\]^ Many studies have investigated the role of mesothelin in tumor biology and suggested its role in proliferation, local invasion, and metastasis. Overexpression of mesothelin has been reported in many solid tumors including mesothelioma, pancreatic cancer, gastric cancer, ovarian cancer, non-small cell lung cancer, and triple-negative breast cancer.^\[[@R6]--[@R11]\]^ Due to its limited expression rate in normal tissue and high expression rate in cancer, therapeutic agents targeting mesothelin have been developed and are currently undergoing clinical trials.^\[[@R12]\]^ Several studies have shown that mesothelin expression is correlated with poor prognosis in stomach cancer and esophageal adenocarcinoma.^\[[@R8],[@R13]--[@R16]\]^

In colorectal adenocarcinoma, mesothelin expression was first described in 2003, and its overexpression was reported in about 50% of colorectal adenocarcinoma cases.^\[[@R17]--[@R19]\]^ Still, studies on the prognostic value of mesothelin in colorectal adenocarcinoma are limited. Kawamata et al showed that luminal staining of mesothelin correlated with lymphatic invasion and lymph node metastasis.^\[[@R19]\]^ Moreover, Shiraishi et al reported that non-luminal staining of mesothelin was associated with shorter cancer-specific survival (CSS) in stage II/III, while luminal staining was not associated with CSS.^\[[@R20]\]^ Molecular heterogeneity in colorectal adenocarcinoma influences patient outcome and response to treatment, especially depending on the state of the microsatellite instability (MSI).^\[[@R21]\]^ However, there are no studies on the prognostic value of mesothelin in colorectal cancer according to MSI status.

In this study, we investigated the clinicopathologic significance of mesothelin expression and its association with survival rates according to MSI molecular subgroups in colorectal adenocarcinoma.

2. Materials and methods
========================

2.1. Patients
-------------

We retrospectively collected the data of 390 patients who had undergone curative resection for primary colorectal adenocarcinoma at Hanyang University Hospital from January 2005 to December 2010. Patients who had received neoadjuvant chemotherapy and/or neoadjuvant radiotherapy, or those who had recurrent colorectal cancer were excluded. We reviewed medical records to determine the following clinical characteristics: age, sex, follow-up interval, survival, recurrence status, and adjuvant treatment application status and type. Two surgical pathologists (H. K. and Y. C.) reviewed pathology reports and hematoxylin and eosin (H&E)-stained slides to define the clinicopathologic characteristics and confirm the diagnosis. Pathologic parameters including TNM stage (8th AJCC) were determined according to a protocol for examining specimens from patients with primary adenocarcinoma of the colon and rectum.^\[[@R22],[@R23]\]^ Pathologic characteristics included tumor size, histologic grade, lymphatic invasion, vascular invasion, perineural invasion, tumor deposit, tumor budding, TNM stage, and MSI status.^\[[@R22],[@R24]\]^ This study was approved by the Institutional Review Board of the Hanyang University Hospital (HYUH 2016--12--030--001), and the requirement for informed consent was waived.

2.2. Tissue microarray construction
-----------------------------------

We used a manual tissue microarrayer (Unitma, Seoul, Korea) for tissue microarray construction from archival formalin-fixed, paraffin-embedded tissue blocks. Representative tumor area was selected by light microscopy of H&E-stained sections. Tissue cylinders (diameter: 2 mm) were punched from a previously marked lesion on each donor block and transferred to the recipient block (Unitma).

2.3. Microsatellite analysis
----------------------------

Microsatellite analysis was performed as previously described using a panel of five National Cancer Institute workshop-recommended consensus microsatellite markers (BAT25, BAT26, D2S123, D17S250, and D5S346).^\[[@R25]\]^ Cases showing a shifting of microsatellites at 2 or more markers were classified as MSI-High. A shifting of microsatellites at one marker was classified as MSI-Low. Microsatellite stable (MSS) and MSI-L were classified as non-MSI-High.

2.4. Immunohistochemical study and interpretation
-------------------------------------------------

The immunohistochemical study for mesothelin expression was performed with 4-μm-thick sections from TMA blocks using the Ventana Benchmark XT automated staining system (Ventana Medical Systems, Tucson, AZ) according to the manufacturer\'s protocol. The rabbit monoclonal anti-mesothelin (1:50; SP74; Abcam, Cambridge, UK) antibody was used for immunohistochemical staining. We evaluated the mesothelin expression according to the staining intensity and extent of the tumor cells. A luminal staining pattern without membranous and/or cytoplasmic staining was observed only in sections with weakly positive staining intensity. In moderately and strongly positive staining sections, both luminal and non-luminal staining patterns (membranous and/or cytoplasmic) were observed simultaneously. The intensity of staining (any pattern, luminal and non-luminal) was graded as negative, weakly positive, moderately positive, or strongly positive (Fig. [1](#F1){ref-type="fig"}). The staining was scored as follows: 0, no expression or any intensity expression less than 5% of tumor cells; 1, weak expression in ≥5% of tumor cells or moderate to strong expression in ≥5% and \<30% of tumor cells; and 2, moderate to strong expression in ≥30% of tumor cells. The cases were subdivided into low expression (score 0--1) and high expression groups (score 2).

![Immunohistochemical staining of mesothelin in colorectal adenocarcinoma. The intensity of membranous and/or cytoplasmic staining was graded as negative (A), weakly positive (B), moderately positive (C), or strongly positive (D) (A--D, ×200).](medi-98-e16207-g001){#F1}

2.5. Statistical analysis
-------------------------

Statistical analysis was performed using SPSS software version 21 (IBM Corp., Armonk, NY). The chi-square and Mann--Whitney *U* tests were used to evaluate the association between mesothelin expression and clinicopathologic characteristics including tumor size, histologic grade, lymphatic invasion, vascular invasion, perineural invasion, tumor deposit, tumor budding, TNM stage, and MSI status. CSS was defined as the time interval between the date of curative resection and the date of death due to colorectal adenocarcinoma. Recurrence-free survival (RFS) was defined as the time interval between curative resection and the date of any recurrence. Kaplan--Meier survival curves, the log-rank test, and the Cox proportional hazard regression model were used for survival analysis. Two-sided *P* values \<.05 were considered statistically significant.

3. Results
==========

3.1. Baseline characteristics of patients
-----------------------------------------

The clinicopathologic characteristics of patients are summarized in Supplemental Table 1. Median follow-up period was 109.5 months (range 1--166), mean age at surgery was 63.4 years (range 27--89), and 237 (60.8%) patients were men with a male-to-female ratio of 1.54:1. Pathological evaluation revealed that 29 tumors (7.4%) were histologic grade 1, 183 (46.9%) were grade 2, 157 (40.2%) were grade 3, and 21 (5.4%) were grade 4. According to 8th AJCC staging system, 55 (14.1%) were stage I, 121 (31.0%) were stage II, 185 (47.4%) were stage III, and 29 (7.4%) were stage IV. Among 390 cases, 363 (93.1%) were non-MSI-High and 27 (6.9%) were MSI-High. Distant metastasis was identified in 29 (7.4%) patients at the time of initial diagnosis, 82 (21.0%) had experienced metastasis or relapse during the follow-up period, and 138 (35.4%) had died due to colorectal adenocarcinoma.

For treatment, 207 (53.1%) patients received curative surgical resection only, and 183 (46.9%) patients received curative surgical resection plus adjuvant chemotherapy (158 cases) or adjuvant combined chemo-radiotherapy (25 cases). The detailed adjuvant chemotherapy regimens are summarized in supplemental Table 1.

3.2. Correlations between mesothelin expression and clinicopathologic characteristics
-------------------------------------------------------------------------------------

Overall, high mesothelin expression was observed in 177 (45.4%) of 390 colorectal cancers. Mesothelin expression was significantly correlated with high histologic grade (*P* = .037), lymphatic invasion (*P* = .028), lymph node metastasis (*P* = .028), and high AJCC stage (*P* = .026). Moreover, mesothelin expression was more frequent in cases with high-grade tumor budding (Table [1](#T1){ref-type="table"}). There was no statistically significant correlation between mesothelin expression and other clinicopathologic parameters. In subgroup analysis, high mesothelin expression was also more frequently observed in cases with lymphatic invasion (*P* = .057), high-grade tumor budding (*P* = .081), lymph node metastasis (*P* = .057), and high AJCC stage (*P* = .055) in the non-MSI-High group. In the MSI-High group, mesothelin expression was significantly correlated with high histologic grade (*P* = .018) and tumor deposit (*P* = .047; Table [2](#T2){ref-type="table"}).

###### 

Correlation between mesothelin expression and clinicopathologic features of colorectal adenocarcinoma patients (n = 390).
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Correlation between mesothelin expression and clinicopathologic features of non-MSI-High (n = 363) and MSI-High (n = 27) colorectal adenocarcinoma patients.
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3.3. Prognostic significance of mesothelin expression
-----------------------------------------------------

There were no significant differences between the high mesothelin expression and low mesothelin expression groups for both RFS and CSS (*P* = .609 and *P* = .167, respectively; Fig. [2](#F2){ref-type="fig"}A--B). In subgroup analyses, there were no significant differences in both the RFS and CSS in the non-MSI-High group (*P* = .870 and *P* = .156, respectively; Fig. [2](#F2){ref-type="fig"} C--D); however, high mesothelin expression was associated with shorter RFS in the MSI-High group (*P* *=* .004; Fig. [2](#F2){ref-type="fig"}E). We additionally divided the groups according to treatment. Mesothelin expression had no prognostic implication for RFS and CSS in both colorectal cancer groups with adjuvant therapy (n = 183; *P* = .944 and *P* = .480, respectively) and without adjuvant therapy (n = 207; *P* = .763 and *P* = .291, respectively).

![Kaplan--Meier survival analysis of recurrence-free survival (RFS) and cancer-specific survival (CSS) in colorectal adenocarcinoma patients. No significant difference in RFS or CSS was observed in all colorectal adenocarcinoma (A--B) and non-MSI-High subgroup (C--D). High mesothelin expression was associated with shorter RFS (E), and no significant difference in CSS (F) was observed in MSI-High subgroup.](medi-98-e16207-g004){#F2}

4. Discussion
=============

In this study, we revealed that mesothelin expression was correlated with aggressive phenotypes in colorectal adenocarcinoma, such as high histologic grade, frequent lymphatic invasion, high-grade tumor budding, lymph node metastasis, and high AJCC stage. Mesothelin was not a prognostic indicator of CSS and RFS in all patients but served as a significant prognostic factor of RFS in the MSI-High group of colorectal adenocarcinoma. Although the number of MSI-high cases was small, this finding is interesting. The survival discrepancy between groups might be explained by their distinct genomic background. Recent studies revealed that MSS/MSI-Low and MSI-High groups of colorectal adenocarcinoma exhibit distinct genomic profiles and show different phenotypes and prognoses. The MSI-High group of colorectal adenocarcinoma patients usually show proximal colon predominance, poor histologic differentiation and/or mucin production, and increased tumor-infiltrating lymphocytes.^\[[@R26]\]^ Several studies have shown that MSI-High colorectal adenocarcinoma has a better prognosis than MSS/MSI-Low colorectal adenocarcinoma.^\[[@R27]\]^ A recent study has revealed that advanced stage MSI-High colorectal adenocarcinoma has higher rates of treatment response and progression-free survival to pembrolizumab, an immunomodulatory drug targeting programmed cell death 1 (PD-1) protein, than MSS/MSI-Low colorectal adenocarcinoma.^\[[@R21]\]^

Mesothelin overexpression in malignancies is associated with tumor cell migration and invasion.^\[[@R6],[@R28]\]^ These findings correspond with our results that mesothelin overexpression correlated with frequent lymphatic invasion and high-grade tumor budding. A previous study demonstrated that mesothelin overexpression promotes tumor cell motility and invasion via the activation of MMP-7 and MMP-9.^\[[@R6],[@R29]\]^

In gastrointestinal tumors, mesothelin expression is a poor prognostic factor.^\[[@R30]\]^ Co-expression of mesothelin and CA125 was associated with poor patient prognosis in pancreatic cancer.^\[[@R7]\]^ Luminal membrane expression of mesothelin was one of the poor prognostic factors in gastric cancer.^\[[@R8]\]^ Intracellular mesothelin expression correlated with poor patient prognosis in extrahepatic bile duct cancer.^\[[@R31]\]^ In several studies, the expression pattern of mesothelin is divided into luminal and non-luminal patterns. In a 2014 study, luminal staining of mesothelin was correlated with poor prognostic factors in colorectal adenocarcinoma.^\[[@R19]\]^ In another recent study, a luminal pattern of mesothelin expression was not associated with CSS and poor prognostic factors; however, a non-luminal pattern of mesothelin expression was associated with CSS and poor prognostic factors, such as tumor budding, high histologic grading, and lymph node metastasis.^\[[@R20]\]^ In the present study, a completely luminal pattern of staining was observed only in cases with weak intensity, while both luminal and non-luminal patterns were observed simultaneously in cases with moderate to strong positive staining. A score of 2 (moderate to strong expression in ≥30% of tumor cells) was considered as high expression. As a result, cases with only a luminal pattern were considered to have low expression, and non-luminal pattern was associated with poor prognostic factors. These findings are consistent with a previous study; although not statistically significant, our study also showed shorter CSS in patients with mesothelin overexpression.^\[[@R20]\]^

Clinical trials of mesothelin-targeting therapy are currently under way for malignant mesothelioma and pancreatic cancer.^\[[@R12]\]^ Mesothelin expression was found in a large number of cases (45.4%) and was associated with poor prognosis. Mesothelin-targeted therapy may be a new treatment candidate for colorectal adenocarcinoma.

5. Conclusion
=============

We revealed that mesothelin expression was significantly associated with aggressive phenotypes in colorectal adenocarcinoma and shorter RFS in the MSI-High group. Further studies are warranted to assess larger cohorts with a large number of MSI-High cases.
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